Daily Digest: Last 9 Hours: Stroke Risk From Recreational Drugs and DEA Scheduling Actions — March 08, 2026
March 08, 2026 — 12 articles reviewed
This cycle was dominated by a single large Cambridge study linking recreational drug use, including cannabis, to significantly elevated stroke risk, especially in younger populations. Alongside that clinical signal, a wave of DEA scheduling actions targeting novel synthetic opioids rounded out a regulatory-heavy news period.
The Cambridge stroke data deserves a permanent place in every clinician’s cannabis counseling toolkit, particularly for younger patients who assume plant-based means risk-free. Screen broadly, counsel specifically, and remember that good medicine means weighing cardiovascular signals just as seriously as we weigh the benefits.
This topic comes up in consultations often.
Dr. Caplan offers clinical context on evolving cannabis policy and its real-world implications for patients.
Book a consultation →
